Loading...
Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in United Kingdom- A pilot randomised controlled trial
Mushtaq, Sohail Agbalalah, Tarimoboere
Mushtaq, Sohail
Agbalalah, Tarimoboere
Advisors
Editors
Other Contributors
Affiliation
EPub Date
Publication Date
2022-04-22
Submitted Date
Collections
Files
Loading...
Article - VoR
Adobe PDF, 620.24 KB
Other Titles
Abstract
Observational studies suggest links between reduced serum 25(OH)D concentration and increased cardiometabolic disease risk. However, these studies provide limited evidence of causation, with few conclusive randomised controlled trials (RCT) having been carried out to date. This RCT investigated the effect of vitamin D3 supplementation on vascular function and cardiometabolic disease risk markers, in fifty-five healthy males aged 18-65 years with plasma 25(OH)D concentration <75nmol/L and BMI ≥24.9kg/m2.
Method
Participants were assigned to consume 125µg/day (5,000 IU/day) vitamin D3 or placebo for 8-weeks. Blood samples and vascular function measures were obtained at baseline, week 4 and week 8. The primary outcome was arterial stiffness, an indicator of cardiovascular diseases risk (CVD), assessed by pulse wave velocity. Biomarkers of CVD risk, insulin resistance and endothelial function were measured using enzyme linked immunosorbent assay.
Results
Daily oral intake of 125µg supplemental vitamin D3 led to a significant improvement in plasma 25(OH)D concentrations over the 8-week intervention in the vitamin D group compared to the change in the placebo group (P ˂ 0.001). In the vitamin D group the baseline mean (±SD) 25(OH)D concentration was 38.4 ± 15.9 and this increased to 72.8 ± 16.1 nmol/L after 8 weeks of supplementation. The intervention had no effect on arterial stiffness, as measured by pulse wave velocity (PWV) but vitamin D3 supplementation did lead to a decrease in mean (±SD) brachial pulse pressure from baseline to 8 weeks, by − 2.9 ± 3.4 mmHg, (P = 0.027) in the vitamin D group compared to the same period in the placebo group. The intervention had no effect on the remaining cardiometabolic parameters.
Conclusion
Overall, treatment significantly improved brachial pulse pressure but no other cardiometabolic disease risk markers. To follow on from this pilot RCT, future large-scale clinical trials over longer durations may offer further insights.
Clinical trial registration
http://www.clinicaltrials.gov NCT02359214.
Citation
Agbalalah, T., & Mushtaq, S. (2023). Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in United Kingdom - A pilot randomised controlled trial. Journal of Human Nutrition and Dietetics, 36(1), 216-225. https://doi.org/10.1111/jhn.13021
Publisher
Wiley
Journal
Journal of Human Nutrition and Dietetics
Research Unit
DOI
10.1111/jhn.13021
PubMed ID
PubMed Central ID
Type
Article
Language
Description
Series/Report no.
ISSN
0952-3871
EISSN
1365-277X